• Secondary hyperparathyroidism in pre-dialysis patients:
    • PO 0.25mcg OD
    • Can be increased 0.25 mcg/day every 4-8 weeks
  • Hypocalcemia in dialysis patients:
    • PO 0.25mcg OD
    • Can be increased 0.25 mcg/day every 4-8 weeks
  • Hypoparathyroidism-associated hypocalcemia:
    • PO 0.25mcg OD
    • Can be increased 0.25 mcg/day every 2-4 weeks
    • For post-surgery, idiopathic or pseudo-hypoparathyroidism
  • Postmenopausal osteoporosis
    • PO 0.25mcg BD
  • Vitamin D-dependent rickets (Off-label):
    • PO 1mcg OD
  • Familial hypophosphatemia (off-label)
    • PO 2mcg OD

Capsule:

  • 0.25mcg
  • Can be taken with meals to avoid GI discomfort

It is the active form of vitamin D, and it is essential for calcium absorption and bone mineralization. It maintains serum calcium levels by increasing calcium absorption in the GI tract. It promotes healthy bone formation by the calcification of osteoid tissue. It also directly inhibits parathyroid gland activity by decreasing parathyroid hormone synthesis and release.

  • Hypercalcemia
  • Hyperphosphatemia
  • Elevated Cr
  • Nausea
  • Vomiting
  • Constipation
  • Anorexia
  • Somnolence
  • Xerostomia
  • Myalgia
  • Bone pain
  • Metallic taste
  • Polyuria
  • Polydipsia
  • Irritability
  • Weight loss
  • Mild acidosis
  • Elevated LFTs
  • Conjunctivitis
  • Photophobia
  • Abdominal discomfort (PO use)
  • Abdominal pain (PO use)
  • Sensory disturbance (PO use)
  • UTI (PO use)
  • Hypersensitivity to drug or ingredient
  • Hypercalcemia
  • Hyperphosphatemia
  • Vitamin D toxicity
  • Malabsorption syndrome
  • Burosumab

                                   Drug Status

Availability Prescription only
Pregnancy Contraindicated
Breastfeeding Contraindicated
Schedule Not controlled
BRAND NAME STRENGTH FORMULATION PACK SIZE MANUFACTURER DISTRIBUTOR
Meditrol 0.25mcg Capsule 30’s Mega Lifesciences Mega Lifesciences